Status:
UNKNOWN
Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Samsung Medical Center
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Kidney transplantation (KT) requires a life-long immune suppression (IS). It has been well-known that long-term IS inevitably causes various complication e.g. infection, toxicity, diabetes, osteoporos...
Eligibility Criteria
Inclusion
- All consenting adult (18 and more years of age) living donor kidney transplant recipients who have a one haplotype match donor.
- Patients who have no known contraindication to administration of rabbit anti-thymocyte globulin (ATG) or radiation.
- Patients who agree to participate in the study and sign an Informed Consent.
Exclusion
- Presence of previous episode of transplantation including kidney
- Simultaneous multi-visceral transplantation
- Demonstration of donor specific antibody (DSA) or panel reactive antibody(PRA) greater than 20%
- ABO blood type incompatible
- Previous treatment with rabbit anti-thymocyte globulin or a known allergy to rabbit proteins.
- History of malignancy with the exception of non-melanoma skin malignancies.
- Uncontrolled systemic or concomitant unstable infection
- Serological evidence of Hepatitis B or Hepatitis C or HIV infection.
- Severe psychiatric disease
- Leukopenia (with a white blood cell count \< 3000/mm3)
- Disagreement to participate in the study and sign an Informed Consent.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT02199301
Start Date
December 1 2011
End Date
December 1 2017
Last Update
July 24 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center, Organ Transplant Center
Seoul, South Korea, 135-710